|
WO2021041972A1
|
|
Anti-il31 antibodies for veterinary use
|
|
WO2021022067A2
|
|
Parvovirus antibodies for veterinary use
|
|
WO2021011645A1
|
|
Equine esomeprazole formulations and methods of use
|
|
WO2020191289A1
|
|
Ngf antagonists for medical use
|
|
WO2020139984A1
|
|
Igg fc variants for veterinary use
|
|
WO2020123849A1
|
|
Erythropoietin analogs for veterinary use
|
|
WO2020086886A1
|
|
Il4/il13 receptor molecule for veterinary use
|
|
AU2019360271A1
|
|
Fc variants with altered binding to neonatal Fc receptor (FcRn) for veterinary use
|
|
AU2019338602A1
|
|
Anti-IL4 receptor antibodies for veterinary use
|
|
US2019374509A1
|
|
Methods of Using Metamizole for Treatment of Pyrexia in Equines
|
|
EP3781197A1
|
|
Variant asparaginase polypeptides for medical use
|
|
AU2018318440A1
|
|
IgG Fc variants for veterinary use
|
|
WO2018236728A1
|
|
Il17a antibodies and antagonists for veterinary use
|
|
BR112019025563A2
|
|
ERYTHROPOIETIN AND ANALOGS FOR VETERINARY USE
|
|
WO2018195388A1
|
|
Il4/il13 receptor molecule for veterinary use
|
|
WO2018156367A1
|
|
Anti-il31 antibodies for veterinary use
|
|
US2018244766A1
|
|
Anti-IL31 antibodies for veterinary use
|
|
US2018071256A1
|
|
Compositions and methods for treatment and prevention of pyrexia in horses
|
|
CA3013771A1
|
|
Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
|
|
WO2015069988A1
|
|
Treatment of pain in animals
|
